Research progress in the diagnosis and treatment of pseudomyxoma peritonei.

Pseudomyxoma Peritonei (PMP) is a rare and complex clinical syndrome characterized by the extensive implantation and metastasis of tumor cells from different tissues within the abdominal cavity, accompanied by the continuous secretion of large amounts of jelly-like mucin. PMP primarily originates from appendiceal mucinous tumors, and in rare cases, can also arise from organs or tissues such as the ovary, colon, gallbladder, pancreas, urachus, small intestine, stomach, intestinal duplications, and teratomas. PMP has diverse clinical manifestations and lacks specificity, making diagnosis difficult, and usually requires comprehensive evaluation in combination with imaging, surgery, and pathological examination. At present, Cytoreductive Surgery (CRS) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) has become its standard treatment regimen. Although this comprehensive therapeutic strategy has significantly improved the overall survival rate of PMP patients, the high postoperative recurrence rate remains a critical factor adversely affecting patient prognosis. This article aims to summarize recent research advances in this field through a literature review, exploring its pathogenesis, clinical manifestations, diagnostic methods, and treatment strategies, with the goal of deepening the understanding of this disease and providing a reference for clinical diagnosis and treatment planning.